Navigation Links
Savient Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
Date:2/23/2012

EAST BRUNSWICK, N.J., Feb. 23, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Kenneth Zuerblis, Executive Vice President and Chief Financial Officer of Savient will present at the Cowen and Company 32nd Annual Health Care Conference on Tuesday, March 6, 2012 at 10:40 AM Eastern Time.  The conference will be held at the Boston Marriott Copley Place in Boston, MA.

A live webcast of the presentation can be accessed through the investor relations section of the Company's website at www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.Contact:  Mary Coleman Carney Noensie Savient Pharmaceuticals, Inc. Burns McClellan information@savient.com  cnoensie@burnsmc.com (732) 418-9300  (212) 213-0006SVNT - G


'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference
2. Savient Pharmaceuticals Appoints David Y. Norton Interim Chief Executive Officer
3. Savient Pharmaceuticals Appoints Experienced Pharmaceutical Executive, David Veitch as President of Savient Europe
4. Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA®
5. Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
6. Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
7. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
8. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
9. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
10. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
11. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2020)... (PRWEB) , ... April 01, 2020 , ... ... allows subscribers to sign up today, with the first live-streaming broadcast premiering on ... weekday and feature a host interviewing a variety of animal keepers and veterinary ...
(Date:3/30/2020)... PARK, N.C. (PRWEB) , ... March 30, 2020 ... ... operations, today announced it has been recognized by Dresner Advisory Services as the ... Zaloni for its capabilities related to data orchestration, data transformation, and data integration ...
(Date:3/30/2020)... SAN DIEGO (PRWEB) , ... March 30, 2020 ... ... the COVID-19 pandemic, Aspire Regenerative now offers telemedicine appointments in addition ... decision to ensure that the safety and well-being of patients, health care professionals, ...
Breaking Medicine Technology:
(Date:4/2/2020)... ... April 02, 2020 , ... Since the onset of the COVID-19 pandemic, there ... GoParrot ( https://www.goparrot.ai/ ) founder Yaniv Nissim has stepped up to the plate ... food safety, has created new standards for delivering food during this time of COVID-19 ...
(Date:4/1/2020)... ... April 02, 2020 , ... Medical Device Change Management, An FDAnews ... , What change management method should one be using for a medical ... on the type of change. Is it due to post-market design change, production process ...
(Date:4/1/2020)... ... 01, 2020 , ... Velocidy Bio ’s Dutch biotech partner, Molecular Biology ... decreases the testing time for SARS-CoV-2 to eight minutes, compared to current systems that ... shoebox could perform a hundred and eighty (180) amplification runs a day, an almost ...
(Date:3/30/2020)... ... March 30, 2020 , ... Achieve Medical Center ... commitment to provide comprehensive and compassionate mental health and wellness services in the ... UpDox platform for telemedicine services including initial consultations, evaluations, and follow-up care. It ...
(Date:3/28/2020)... ... 2020 , ... With social distancing, or more accurately physical ... people of all ages are challenged to find different ways to connect socially. ... best of times—the physical distance mandated to prevent the pandemic’s spread can be ...
Breaking Medicine News(10 mins):